Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31480016 | 0.99 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBOPRD1LMNA | |
| SCHEMBL31479993 | 0.88 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1POLBOPRD1LMNA | |
| SCHEMBL8922653 | 0.80 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1POLBLMNATP53 | |
| Phenampromide SCHEMBL907884 | 0.77 | OPRM1 (0.47) | SMN1; SMN2ALDH1A1POLBHTTOPRM1 | |
| Phenampromide SCHEMBL907886 | 0.77 | OPRM1 (0.47) | SMN1; SMN2ALDH1A1POLBHTTOPRM1 | |
| Phenampromide SCHEMBL11661877 | 0.76 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBHTTOPRM1 | |
| Phenampromide SCHEMBL11661873 | 0.76 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBHTTOPRM1 | |
| SCHEMBL9155525 | 0.75 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1POLBLMNATP53 | |
| SCHEMBL12821356 | 0.75 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1LMNATP53MAPK1 | |
| SCHEMBL22406302 | 0.74 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1POLBLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051434-A1 | MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051434-A1 | MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS | IL2RA, IL2, FCGR2A | SMN1; SMN2 3186/4885ALDH1A1 4345/4885POLB 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.